Truvada’s annual price is $20,000 in the US and $100 elsewhere…why?

Gilead Sciences Inc.'s Truvada is arranged for an illustration at Ansonia Pharmacy in New York, U.S., on Thursday, July 24, 2008. (Image: JB Reed/Bloomberg News)

Gilead Sciences Inc. CEO Daniel O’Day has only been on the job since March, and he’s already found himself having to defend his company in front of  the House Oversight and Reform committee.

O’Day faced questioning at a Thursday hearing…